Abstract 315P
Background
Based on PRIMA and PRIME, Niraparib is approved by FDA and NMPA for first-line maintenance of OC regardless of biomarker status. Niraparib is widely used in China, while its efficacy and safety in real world remains to be verified. The purpose of this study was to evaluate the efficacy and safety of niraparib as maintenance in newly diagnosed advanced OC.
Methods
We retrospectively collected patients with pathologically confirmed diagnosis of OC, who received niraparib as first-line maintenance therapy at the Department of Gynecology, Tianjin Cancer Hospital between January 2021 and December 2022. Demographics, baseline characteristics, clinical outcomes and adverse events were collected. The history of niraparib use, including the time from the end of chemotherapy to the start of maintenance therapy, the starting dose, and the stable dose used after 3 months, were also collected.
Results
102 patients were enrolled. The median age was 58 years and 84.3% were FIGO stage III/IV. 18.6% BRCAmut, 58.8% BRCAwt and 22.5% BRCAunkown, while 36.3% HRD deficient, 12.7% HRD proficient and 51% HRD unkown. 53.9% received NACT, 76.5% were R0 after surgery and 62.7% were CR after chemotherapy. Median follow-up was 10.5m. In the ITT population, the mPFS was not reached, with a 24-month PFS rate of 52.5%. The mPFS of BRCAmut, BRCAwt, and BRCAunknown was not reached, 14.4 and 14.6m, respectively. The 24-month PFS rates were 90%, 48.4% and 37.9%, respectively. The mPFS of HRD deficient and HRD proficient were both not reached. 84.3% of patients experienced any grade TEAEs, while 17.6% experienced TEAEs of grade ≥3. TEAEs leading to treatment interruption was 36.3%, leading to dose reduction was 29.4%, leading to discontinuation was 0.98%. The most common hematological TEAEs were platelet count decreased (28.4%) while grade ≥3 TEAEs was 5.9%, white blood cell count decreased (20.6%) and neutrophil count decreased (26.5%). Non-hematologic TEAEs were nausea (31.4%), fatigue (30.4%) and insomnia (21.6%).
Conclusions
In the real world, niraparib maintenance in newly diagnosed advanced OC is effective and safe, which was consistent with previous RCT. More clinical related factors affecting prognosis will be further explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tianjin Medical University Cancer Institute & Hospital.
Funding
Committee of Gynecological Oncology, Tianjin anti-cancer association.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract